Cargando…
Evolution by innovation as a driving force to improve TCR-T therapies
Adoptive cell therapies continually evolve through science-based innovation. Specialized innovations for TCR-T therapies are described here that are embedded in an End-to-End Platform for TCR-T Therapy Development which aims to provide solutions for key unmet patient needs by addressing challenges o...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552759/ https://www.ncbi.nlm.nih.gov/pubmed/37810959 http://dx.doi.org/10.3389/fonc.2023.1216829 |
_version_ | 1785116026152681472 |
---|---|
author | Schendel, Dolores J. |
author_facet | Schendel, Dolores J. |
author_sort | Schendel, Dolores J. |
collection | PubMed |
description | Adoptive cell therapies continually evolve through science-based innovation. Specialized innovations for TCR-T therapies are described here that are embedded in an End-to-End Platform for TCR-T Therapy Development which aims to provide solutions for key unmet patient needs by addressing challenges of TCR-T therapy, including selection of target antigens and suitable T cell receptors, generation of TCR-T therapies that provide long term, durable efficacy and safety and development of efficient and scalable production of patient-specific (personalized) TCR-T therapy for solid tumors. Multiple, combinable, innovative technologies are used in a systematic and sequential manner in the development of TCR-T therapies. One group of technologies encompasses product enhancements that enable TCR-T therapies to be safer, more specific and more effective. The second group of technologies addresses development optimization that supports discovery and development processes for TCR-T therapies to be performed more quickly, with higher quality and greater efficiency. Each module incorporates innovations layered onto basic technologies common to the field of immunology. An active approach of “evolution by innovation” supports the overall goal to develop best-in-class TCR-T therapies for treatment of patients with solid cancer. |
format | Online Article Text |
id | pubmed-10552759 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105527592023-10-06 Evolution by innovation as a driving force to improve TCR-T therapies Schendel, Dolores J. Front Oncol Oncology Adoptive cell therapies continually evolve through science-based innovation. Specialized innovations for TCR-T therapies are described here that are embedded in an End-to-End Platform for TCR-T Therapy Development which aims to provide solutions for key unmet patient needs by addressing challenges of TCR-T therapy, including selection of target antigens and suitable T cell receptors, generation of TCR-T therapies that provide long term, durable efficacy and safety and development of efficient and scalable production of patient-specific (personalized) TCR-T therapy for solid tumors. Multiple, combinable, innovative technologies are used in a systematic and sequential manner in the development of TCR-T therapies. One group of technologies encompasses product enhancements that enable TCR-T therapies to be safer, more specific and more effective. The second group of technologies addresses development optimization that supports discovery and development processes for TCR-T therapies to be performed more quickly, with higher quality and greater efficiency. Each module incorporates innovations layered onto basic technologies common to the field of immunology. An active approach of “evolution by innovation” supports the overall goal to develop best-in-class TCR-T therapies for treatment of patients with solid cancer. Frontiers Media S.A. 2023-09-21 /pmc/articles/PMC10552759/ /pubmed/37810959 http://dx.doi.org/10.3389/fonc.2023.1216829 Text en Copyright © 2023 Schendel https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Schendel, Dolores J. Evolution by innovation as a driving force to improve TCR-T therapies |
title | Evolution by innovation as a driving force to improve TCR-T therapies |
title_full | Evolution by innovation as a driving force to improve TCR-T therapies |
title_fullStr | Evolution by innovation as a driving force to improve TCR-T therapies |
title_full_unstemmed | Evolution by innovation as a driving force to improve TCR-T therapies |
title_short | Evolution by innovation as a driving force to improve TCR-T therapies |
title_sort | evolution by innovation as a driving force to improve tcr-t therapies |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552759/ https://www.ncbi.nlm.nih.gov/pubmed/37810959 http://dx.doi.org/10.3389/fonc.2023.1216829 |
work_keys_str_mv | AT schendeldoloresj evolutionbyinnovationasadrivingforcetoimprovetcrttherapies |